secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2021-11-30T23:59:59+00:00
Accession:  0001104659-21-144727
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage appoints David Green as interim CEO; he invests $250,000 in private placement
--------------------------------------------------------------------------------

- David Green appointed Interim CEO and Chairman; Jason Chen becomes Vice Chairman.
- Green invests $250,000 for 72,464 shares and warrant for 36,232 shares at $3.45 (50% premium to Nov 26 close).
- Green's salary set at Massachusetts minimum wage ($35,568) plus option grant of 374,094 shares (2/3 vest on milestones).
- Green previously served as CEO and Chairman until 2015; returns to lead Biostage's esophageal implant development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465921144727/0001104659-21-144727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465921144727/tm2134175d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-144727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer